Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that PharmAla has completed the first sale of a quantity of Mindset's cGMP (i.e. pharmaceutical grade) psilocybin under their exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX listed Little Green Pharma. Reset recently received human research ethics committee approval for a clinical trial investigating psilocybin assisted psychotherapy protocols for patients with treatment resistant major depressive disorder.